Anthony Petrone
Stock Analyst at Jefferies
(3.94)
# 553
Out of 4,759 analysts
163
Total ratings
52.14%
Success rate
8.83%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $54 → $58 | $46.47 | +24.81% | 2 | Mar 6, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $60 | $39.17 | +53.18% | 8 | Feb 26, 2025 | |
| GKOS Glaukos | Upgrades: Outperform | $140 → $200 | $104.19 | +91.96% | 7 | Feb 19, 2025 | |
| HOLX Hologic | Maintains: Outperform | $90 → $87 | $64.54 | +34.80% | 8 | Nov 5, 2024 | |
| TFX Teleflex | Maintains: Neutral | $275 → $250 | $139.85 | +78.76% | 7 | Nov 1, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $100 → $110 | $99.13 | +10.97% | 8 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Neutral | $115 → $130 | $137.14 | -5.21% | 4 | Oct 17, 2024 | |
| ADMA ADMA Biologics | Maintains: Buy | $12 → $14 | $17.02 | -17.74% | 6 | Jun 20, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $65 → $70 | $41.70 | +67.87% | 6 | Jun 6, 2024 | |
| ALC Alcon | Maintains: Buy | $100 → $105 | $93.03 | +12.87% | 8 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $18.34 | +199.89% | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $100 | $106.34 | -5.96% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $86.58 | +21.28% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $5.77 | +177.30% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $70.33 | +49.30% | 7 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 | $232.44 | -7.50% | 15 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $183.23 | +36.44% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $7.89 | +77.44% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $103 → $115 | $85.00 | +35.29% | 14 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $98 | $94.50 | +3.70% | 4 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $518.26 | -24.75% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $81.37 | -17.66% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $115 | $68.70 | +67.39% | 14 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $107.99 | +62.05% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $12.81 | +95.16% | 3 | May 13, 2020 |
Tarsus Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $46.47
Upside: +24.81%
LivaNova
Feb 26, 2025
Maintains: Outperform
Price Target: $70 → $60
Current: $39.17
Upside: +53.18%
Glaukos
Feb 19, 2025
Upgrades: Outperform
Price Target: $140 → $200
Current: $104.19
Upside: +91.96%
Hologic
Nov 5, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $64.54
Upside: +34.80%
Teleflex
Nov 1, 2024
Maintains: Neutral
Price Target: $275 → $250
Current: $139.85
Upside: +78.76%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $99.13
Upside: +10.97%
Abbott Laboratories
Oct 17, 2024
Maintains: Neutral
Price Target: $115 → $130
Current: $137.14
Upside: -5.21%
ADMA Biologics
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $17.02
Upside: -17.74%
Establishment Labs Holdings
Jun 6, 2024
Maintains: Buy
Price Target: $65 → $70
Current: $41.70
Upside: +67.87%
Alcon
May 15, 2024
Maintains: Buy
Price Target: $100 → $105
Current: $93.03
Upside: +12.87%
May 8, 2024
Maintains: Buy
Price Target: $53 → $55
Current: $18.34
Upside: +199.89%
May 3, 2024
Maintains: Buy
Price Target: $90 → $100
Current: $106.34
Upside: -5.96%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $86.58
Upside: +21.28%
Apr 11, 2024
Maintains: Neutral
Price Target: $20 → $16
Current: $5.77
Upside: +177.30%
Apr 11, 2024
Maintains: Buy
Price Target: $95 → $105
Current: $70.33
Upside: +49.30%
Mar 27, 2024
Maintains: Buy
Price Target: $215
Current: $232.44
Upside: -7.50%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $183.23
Upside: +36.44%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $7.89
Upside: +77.44%
Mar 1, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $85.00
Upside: +35.29%
Feb 21, 2024
Maintains: Buy
Price Target: $95 → $98
Current: $94.50
Upside: +3.70%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $518.26
Upside: -24.75%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $81.37
Upside: -17.66%
Feb 8, 2023
Maintains: Buy
Price Target: $110 → $115
Current: $68.70
Upside: +67.39%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $107.99
Upside: +62.05%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $12.81
Upside: +95.16%